VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

MPN Congress 2022 | Why is CALR an ideal immunotherapeutic target for MPNs?

Ann Mullally, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the potential of calreticulin (CALR) as a therapeutic target in myeloproliferative neoplasms (MPNs), highlighting three recent studies that developed and evaluated antibodies against mutant CALR in pre-clinical models. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter